OBJECTIVE: To assess the feasibility of sentinel node biopsy (SNB) in ductal and lobular invasive breast cancer, a group of tumors known as special histologic type (SHT) of breast cancer. MATERIALS AND METHODS: Between January 1997 and July 2008, 2253 patients from 6 affiliated hospitals underwent SNB who had early breast cancer and clinically negative axilla. The patients' data were collected in a multicenter database. For lymphatic mapping, all patients received an intralesional dose of radiocolloid Tc-99m (4mCi in 0.4 mL saline), at least two hours before the surgical procedure. SNB was performed by physicians from the same nuclear medicine department in all cases. RESULTS: Of the 2253 patients in the database, the SN identification rate was 94.5% (no radiotracer migration in 123 patients), and positive sentinel node prevalence was 22%. SHT was reported in 144 patients (6.4%) of the whole series. In this subgroup, migration of radiotracer was unsuccessful in 8 patients (identification rate was 94.4%) and SNs were positive in 7.4%. SN positivity prevalence in these tumors was variable across the subtypes. Higher probability of lymphatic spread seemed to be related to tumor invasiveness (20% of positivity in micropapillary, 15% in cribriform subtypes, and 0% in adenoid-cystic). CONCLUSION: Sentinel node biopsy is feasible in special histologic subtypes of breast carcinoma with a good identification rate. Lower migration rates, however, might be associated with special histologic features (colloid subtype). Complete axillary dissection after a positive sentinel node cannot be omitted in patients with SHT breast cancer because they can be associated with further axillary disease; the reported very low incidence of axillary metastases would justify avoiding axillary dissection only in the adenoid-cystic subtype.
OBJECTIVE: To assess the feasibility of sentinel node biopsy (SNB) in ductal and lobular invasive breast cancer, a group of tumors known as special histologic type (SHT) of breast cancer. MATERIALS AND METHODS: Between January 1997 and July 2008, 2253 patients from 6 affiliated hospitals underwent SNB who had early breast cancer and clinically negative axilla. The patients' data were collected in a multicenter database. For lymphatic mapping, all patients received an intralesional dose of radiocolloid Tc-99m (4mCi in 0.4 mL saline), at least two hours before the surgical procedure. SNB was performed by physicians from the same nuclear medicine department in all cases. RESULTS: Of the 2253 patients in the database, the SN identification rate was 94.5% (no radiotracer migration in 123 patients), and positive sentinel node prevalence was 22%. SHT was reported in 144 patients (6.4%) of the whole series. In this subgroup, migration of radiotracer was unsuccessful in 8 patients (identification rate was 94.4%) and SNs were positive in 7.4%. SN positivity prevalence in these tumors was variable across the subtypes. Higher probability of lymphatic spread seemed to be related to tumor invasiveness (20% of positivity in micropapillary, 15% in cribriform subtypes, and 0% in adenoid-cystic). CONCLUSION: Sentinel node biopsy is feasible in special histologic subtypes of breast carcinoma with a good identification rate. Lower migration rates, however, might be associated with special histologic features (colloid subtype). Complete axillary dissection after a positive sentinel node cannot be omitted in patients with SHT breast cancer because they can be associated with further axillary disease; the reported very low incidence of axillary metastases would justify avoiding axillary dissection only in the adenoid-cystic subtype.
Entities:
Keywords:
Sentinel lymph node biopsy; breast cancer; invasiveness
Authors: Sandra L Wong; Celia Chao; Michael J Edwards; David J Carlson; Alison Laidley; R Dirk Noyes; Terre McGlothin; Philip B Ley; Todd Tuttle; Mark Schadt; Robert Pennington; Mary Legenza; James Morgan; Kelly M McMasters Journal: Am J Surg Date: 2002-12 Impact factor: 2.565
Authors: Anees B Chagpar; Robert C Martin; Charles R Scoggins; David J Carlson; Alison L Laidley; Souzan E El-Eid; Terre Q McGlothin; Robert D Noyes; Phillip B Ley; Todd M Tuttle; Kelly M McMasters Journal: Surgery Date: 2005-07 Impact factor: 3.982
Authors: U Veronesi; G Paganelli; G Viale; V Galimberti; A Luini; S Zurrida; C Robertson; V Sacchini; P Veronesi; E Orvieto; C De Cicco; M Intra; G Tosi; D Scarpa Journal: J Natl Cancer Inst Date: 1999-02-17 Impact factor: 13.506
Authors: Robert C G Martin; Anees Chagpar; Charles R Scoggins; Michael J Edwards; Lee Hagendoorn; Arnold J Stromberg; Kelly M McMasters Journal: Ann Surg Date: 2005-06 Impact factor: 12.969
Authors: Anees B Chagpar; Charles R Scoggins; Robert C G Martin; Sunati Sahoo; David J Carlson; Alison L Laidley; Souzan E El-Eid; Terre Q McGlothin; Kelly M McMasters Journal: Breast J Date: 2007 May-Jun Impact factor: 2.431
Authors: D Krag; D Weaver; T Ashikaga; F Moffat; V S Klimberg; C Shriver; S Feldman; R Kusminsky; M Gadd; J Kuhn; S Harlow; P Beitsch Journal: N Engl J Med Date: 1998-10-01 Impact factor: 91.245
Authors: Diego Augusto Santos Silva; Mark Stephen Tremblay; Maria de Fatima Marinho de Souza; Maximiliano Ribeiro Guerra; Meghan Mooney; Mohsen Naghavi; Deborah Carvalho Malta Journal: Sci Rep Date: 2018-07-24 Impact factor: 4.379